RxDoctor Payments DataLook up a doctor →

Maria Rosa Costanzo, MD

Advanced Heart Failure and Transplant Cardiology · Naperville, ILNPI 1073564860

Payments from drug & device makers

$1,570,276in general payments, 2019–2025

Across 481 payments — averaging $3264.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$599K
  • Nuwellis, Inc.$369K
  • Boehringer Ingelheim International GmbH$228K
  • Novartis$142K
  • Bayer$39K
  • Merck$32K
  • plus $160K from 20 others
$103in research payments, 2019–2025

Across 2 payments — averaging $51.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$103

What the payments were for

  • Consulting fees$220,82931%
  • Speaking & faculty fees$378,90453%
  • Travel & lodging$53,8848%
  • Food & beverage$62,5369%
  • Education$40%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,570,276 in reported general payments places this provider in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$29,387
Medicare patients
141
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan265$427,505
JardianceEmpagliflozin234$348,188
VyndamaxTafamidis11$256,202
UptraviSelexipag11$239,647
OpsumitMacitentan18$228,833
FarxigaDapagliflozin Propanediol116$132,484
Ambrisentan18$114,012
EliquisApixaban76$78,251
XareltoRivaroxaban43$41,870
Repatha SureclickEvolocumab37$36,369
Eplerenone183$12,746
Metoprolol Succinate398$6,981
Tacrolimus24$5,192
Ranolazine ErRanolazine11$3,899
Carvedilol ErCarvedilol Phosphate11$3,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$142,084$427,505265 claims
Boehringer IngelheimJardiance$12,445$348,188234 claims
AstraZenecaFarxiga$2,539$132,484116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →